Multiplexed RNAi therapy against brain tumor-initiating cells via lipopolymeric nanoparticle infusion delays glioblastoma progression

Proceedings of the National Academy of Sciences of the United States of America

Volumn 114, Issue 30, 2017, Pages E6147-E6156

  Yu, Dou ^a   Khan, Omar F ^b   Suvà, Mario L ^c,d   Dong, Biqin ^e   Panek, Wojciech K ^a   Xiao, Ting ^a   Wu, Meijing ^a   Han, Yu ^a   Ahmed, Atique U ^a   Balyasnikova, Irina V ^a   Zhang, Hao F ^e   Sun, Cheng ^e   Langer, Robert ^b   Anderson, Daniel G ^b   Lesniak, Maciej S ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b Massachusetts Institute of Technology   (United States)

^c BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e Northwestern University   (United States)

Author keywords

Brain tumor initiating cells; Convection enhanced delivery; Glioblastoma transcription factor; Lipopolymeric nanoparticle; SiRNA

Indexed keywords

LIPOPOLYMERIC NANOPARTICLE 7C1; NANOPARTICLE; OLIGODENDROCYTE TRANSCRIPTION FACTOR 2; POLYMER; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR POU3F2; TRANSCRIPTION FACTOR SALL2; TRANSCRIPTION FACTOR SOX2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN TUMOR INITIATING CELL; CANCER GROWTH; CANCER INHIBITION; CELL DEATH; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; GENE SILENCING; GENE TARGETING; GLIOBLASTOMA; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NANOENCAPSULATION; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNAI THERAPEUTICS; THERMODYNAMICS; TUMOR CELL; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT; ANIMAL; CARCINOGENESIS; DRUG RESISTANCE; DRUG SCREENING; GENE THERAPY; GENETICS; NUDE MOUSE; PATHOLOGY; PROCEDURES; RNA INTERFERENCE;

ANIMALS; CARCINOGENESIS; DRUG RESISTANCE, NEOPLASM; FEMALE; GENETIC THERAPY; GLIOBLASTOMA; HUMANS; MALE; MICE; MICE, NUDE; NANOPARTICLES; RNA INTERFERENCE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85025680489     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1701911114     Document Type: Article

References (81)

1. Wen PY, Reardon DA (2016) Neuro-oncology in 2015: Progress in glioma diagnosis, classification and treatment. Nat Rev Neurol 12:69–70.
2. Van Meir EG, et al. (2010) Exciting new advances in neuro-oncology: The avenue to a cure for malignant glioma. CA Cancer J Clin 60:166–193.
3. Hambardzumyan D, Bergers G (2015) Glioblastoma: Defining tumor niches. Trends Cancer 1:252–265.
4. Ellis HP, et al. (2015) Current challenges in glioblastoma: Intratumour heterogeneity, residual disease, and models to predict disease recurrence. Front Oncol 5:251.
5. Seymour T, Nowak A, Kakulas F (2015) Targeting Aggressive cancer stem cells in glioblastoma. Front Oncol 5:159.
6. Lee JK, Nam DH, Lee J (2016) Repurposing antipsychotics as glioblastoma therapeutics: Potentials and challenges. Oncol Lett 11:1281–1286.
7. Yan K, Yang K, Rich JN (2013) The evolving landscape of glioblastoma stem cells. Curr Opin Neurol 26:701–707.
8. Lathia JD, Mack SC, Mulkearns-Hubert EE, Valentim CL, Rich JN (2015) Cancer stem cells in glioblastoma. Genes Dev 29:1203–1217.
9. Hjelmeland AB, Lathia JD, Sathornsumetee S, Rich JN (2011) Twisted tango: Brain tumor neurovascular interactions. Nat Neurosci 14:1375–1381.
10. Li Z, Rich JN (2010) Hypoxia and hypoxia inducible factors in cancer stem cell maintenance. Curr Top Microbiol Immunol 345:21–30.
11. Ricci-Vitiani L, et al. (2010) Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 468:824–828.
12. Francescone R, et al. (2012) Glioblastoma-derived tumor cells induce vasculogenic mimicry through Flk-1 protein activation. J Biol Chem 287:24821–24831.
13. El Hallani S, et al. (2010) A new alternative mechanism in glioblastoma vascularization: Tubular vasculogenic mimicry. Brain 133:973–982.
14. Yin H, et al. (2016) Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo. Nat Biotechnol 34:328–333.
15. Xue W, et al. (2014) Small RNA combination therapy for lung cancer. Proc Natl Acad Sci USA 111:E3553–E3561.
16. Sager HB, et al. (2016) RNAi targeting multiple cell adhesion molecules reduces immune cell recruitment and vascular inflammation after myocardial infarction. Sci Transl Med 8:342ra80.
17. Platt RJ, et al. (2014) CRISPR-Cas9 knockin mice for genome editing and cancer modeling. Cell 159:440–455.
18. Lee H, et al. (2012) Molecularly self-assembled nucleic acid nanoparticles for targeted in vivo siRNA delivery. Nat Nanotechnol 7:389–393.
19. Khan OF, et al. (2015) Dendrimer-inspired nanomaterials for the in vivo delivery of siRNA to lung vasculature. Nano Lett 15:3008–3016.
20. Fenton OS, et al. (2016) Bioinspired alkenyl amino alcohol ionizable lipid materials for highly potent in vivo mRNA delivery. Adv Mater 28:2939–2943.
21. Dong Y, et al. (2014) Lipopeptide nanoparticles for potent and selective siRNA delivery in rodents and nonhuman primates. Proc Natl Acad Sci USA 111:3955–3960.
22. Chen D, et al. (2012) Rapid discovery of potent siRNA-containing lipid nanoparticles enabled by controlled microfluidic formulation. J Am Chem Soc 134:6948–6951.
23. Dahlman JE, et al. (2014) In vivo endothelial siRNA delivery using polymeric nanoparticles with low molecular weight. Nat Nanotechnol 9:648–655.
24. Suvà ML, et al. (2014) Reconstructing and reprogramming the tumor-propagating potential of glioblastoma stem-like cells. Cell 157:580–594.
25. Rheinbay E, et al. (2013) An aberrant transcription factor network essential for Wnt signaling and stem cell maintenance in glioblastoma. Cell Reports 3:1567–1579.
26. Mao P, et al. (2013) Mesenchymal glioma stem cells are maintained by activated glycolytic metabolism involving aldehyde dehydrogenase 1A3. Proc Natl Acad Sci USA 110:8644–8649.
27. Kim SH, et al. (2016) Serine/threonine kinase MLK4 determines mesenchymal identity in glioma stem cells in an NF-κB-dependent manner. Cancer Cell 29:201–213.
28. Cheng P, et al. (2016) FOXD1-ALDH1A3 signaling is a determinant for the self-renewal and tumorigenicity of mesenchymal glioma stem cells. Cancer Res 76:7219–7230.
29. Han L, et al. (2010) Tat-BMPs-PAMAM conjugates enhance therapeutic effect of small interference RNA on U251 glioma cells in vitro and in vivo. Hum Gene Ther 21: 417–426.
30. Van Woensel M, et al. (2016) Development of siRNA-loaded chitosan nanoparticles targeting Galectin-1 for the treatment of glioblastoma multiforme via intranasal administration. J Control Release 227:71–81.
31. Lee TJ, et al. (2015) RNA nanoparticle as a vector for targeted siRNA delivery into glioblastoma mouse model. Oncotarget 6:14766–14776.
32. Kozielski KL, Tzeng SY, De Mendoza BA, Green JJ (2014) Bioreducible cationic polymer-based nanoparticles for efficient and environmentally triggered cytoplasmic siRNA delivery to primary human brain cancer cells. ACS Nano 8:3232–3241.
33. Danhier F, Messaoudi K, Lemaire L, Benoit JP, Lagarce F (2015) Combined anti-Galectin-1 and anti-EGFR siRNA-loaded chitosan-lipid nanocapsules decrease temo-zolomide resistance in glioblastoma: In vivo evaluation. Int J Pharm 481:154–161.
34. Cohen ZR, et al. (2015) Localized RNAi therapeutics of chemoresistant grade IV glioma using hyaluronan-grafted lipid-based nanoparticles. ACS Nano 9:1581–1591.
35. Jensen SA, et al. (2013) Spherical nucleic acid nanoparticle conjugates as an RNAi-based therapy for glioblastoma. Sci Transl Med 5:209ra152.
36. Wakimoto H, et al. (2009) Human glioblastoma-derived cancer stem cells: Establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors. Cancer Res 69:3472–3481.
37. Sarkaria JN, et al. (2006) Use of an orthotopic xenograft model for assessing the effect of epidermal growth factor receptor amplification on glioblastoma radiation response. Clin Cancer Res 12:2264–2271.
38. Verhaak RG, et al.; Cancer Genome Atlas Research Network (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17:98–110.
39. Wittrup A, Lieberman J (2015) Knocking down disease: A progress report on siRNA therapeutics. Nat Rev Genet 16:543–552.
40. Fire A, et al. (1998) Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391:806–811.
41. Song E, et al. (2003) RNA interference targeting Fas protects mice from fulminant hepatitis. Nat Med 9:347–351.
42. Dahlman JE, et al. (2015) Orthogonal gene knockout and activation with a catalyti-cally active Cas9 nuclease. Nat Biotechnol 33:1159–1161.
43. Jhaveri N, Chen TC, Hofman FM (2016) Tumor vasculature and glioma stem cells: Contributions to glioma progression. Cancer Lett 380:545–551.
44. Cheng L, et al. (2013) Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth. Cell 153:139–152.
45. Gilbertson RJ, Rich JN (2007) Making a tumour’s bed: Glioblastoma stem cells and the vascular niche. Nat Rev Cancer 7:733–736.
46. Hovinga KE, et al. (2010) Inhibition of notch signaling in glioblastoma targets cancer stem cells via an endothelial cell intermediate. Stem Cells 28:1019–1029.
47. Seidel S, et al. (2010) A hypoxic niche regulates glioblastoma stem cells through hypoxia inducible factor 2 alpha. Brain 133:983–995.
48. Yu D, et al. (2013) Alleviation of chronic pain following rat spinal cord compression injury with multimodal actions of huperzine A. Proc Natl Acad Sci USA 110:E746–E755.
49. Patel AP, et al. (2014) Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science 344:1396–1401.
50. Bao S, et al. (2006) Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444:756–760.
51. Chen J, et al. (2012) A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 488:522–526.
52. Singh SK, et al. (2004) Identification of human brain tumour initiating cells. Nature 432:396–401.
53. Son MJ, Woolard K, Nam DH, Lee J, Fine HA (2009) SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma. Cell Stem Cell 4:440–452.
54. Anido J, et al. (2010) TGF-β receptor inhibitors target the CD44(high)/Id1(high) glioma-initiating cell population in human glioblastoma. Cancer Cell 18:655–668.
55. Lathia JD, et al. (2010) Integrin alpha 6 regulates glioblastoma stem cells. Cell Stem Cell 6:421–432.
56. Takahashi K, et al. (2007) Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131:861–872.
57. Takahashi K, Yamanaka S (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126:663–676.
58. Ito K, et al. (2008) PML targeting eradicates quiescent leukaemia-initiating cells. Nature 453:1072–1078.
59. Stricker SH, et al. (2013) Widespread resetting of DNA methylation in glioblastoma-initiating cells suppresses malignant cellular behavior in a lineage-dependent manner. Genes Dev 27:654–669.
60. Piccirillo SG, et al. (2006) Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature 444:761–765.
61. Lee J, et al. (2006) Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 9:391–403.
62. Natsume A, et al. (2013) Chromatin regulator PRC2 is a key regulator of epigenetic plasticity in glioblastoma. Cancer Res 73:4559–4570.
63. Jahani-Asl A, et al. (2016) Control of glioblastoma tumorigenesis by feed-forward cytokine signaling. Nat Neurosci 19:798–806.
64. Furnari FB, Cloughesy TF, Cavenee WK, Mischel PS (2015) Heterogeneity of epidermal growth factor receptor signalling networks in glioblastoma. Nat Rev Cancer 15: 302–310.
65. Wei W, et al. (2016) Single-cell phosphoproteomics resolves adaptive signaling dynamics and informs targeted combination therapy in glioblastoma. Cancer Cell 29: 563–573.
66. Lu F, et al. (2016) Olig2-dependent reciprocal shift in PDGF and EGF receptor signaling regulates tumor phenotype and mitotic growth in malignant glioma. Cancer Cell 29: 669–683.
67. Liu F, et al. (2015) EGFR mutation promotes glioblastoma through epigenome and transcription factor network remodeling. Mol Cell 60:307–318.
68. Rozhkova EA (2011) Nanoscale materials for tackling brain cancer: Recent progress and outlook. Adv Mater 23:H136–H150.
69. Yang XZ, et al. (2012) Sheddable ternary nanoparticles for tumor acidity-targeted siRNA delivery. ACS Nano 6:771–781.
70. Chahal JS, et al. (2016) Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and Toxoplasma gondii challenges with a single dose. Proc Natl Acad Sci USA 113:E4133–E4142.
71. Jahangiri A, et al. (2017) Convection-enhanced delivery in glioblastoma: A review of preclinical and clinical studies. J Neurosurg 126:191–200.
72. Vogelbaum MA, Aghi MK (2015) Convection-enhanced delivery for the treatment of glioblastoma. Neuro-oncol 17:ii3–ii8.
73. Saucier-Sawyer JK, et al. (2016) Distribution of polymer nanoparticles by convection-enhanced delivery to brain tumors. J Control Release 232:103–112.
74. Debinski W, Tatter SB (2010) Convection-enhanced delivery to achieve widespread distribution of viral vectors: Predicting clinical implementation. Curr Opin Mol Ther 12:647–653.
75. Robbins M, et al. (2008) Misinterpreting the therapeutic effects of small interfering RNA caused by immune stimulation. Hum Gene Ther 19:991–999.
76. Judge AD, et al. (2005) Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol 23:457–462.
77. Hu Y, Smyth GK (2009) ELDA: Extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J Immunol Methods 347:70–78.
78. Ahmed AU, et al. (2013) A preclinical evaluation of neural stem cell-based cell carrier for targeted antiglioma oncolytic virotherapy. J Natl Cancer Inst 105:968–977.
79. Dong B, et al. (2016) Super-resolution spectroscopic microscopy via photon localization. Nat Commun 7:12290.
80. Dong B, et al. (2016) Superresolution intrinsic fluorescence imaging of chromatin utilizing native, unmodified nucleic acids for contrast. Proc Natl Acad Sci USA 113: 9716–9721.
81. Ovesný M, Krízek P, Borkovec J, Svindrych Z, Hagen GM (2014) ThunderSTORM: A comprehensive ImageJ plug-in for PALM and STORM data analysis and super-resolution imaging. Bioinformatics 30:2389–2390.